MA55609A - TRI-SPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING A BI-VARIABLE CROSS-DOMAIN FORMAT (CODV) FOR THE TREATMENT OF HIV INFECTION - Google Patents

TRI-SPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING A BI-VARIABLE CROSS-DOMAIN FORMAT (CODV) FOR THE TREATMENT OF HIV INFECTION

Info

Publication number
MA55609A
MA55609A MA055609A MA55609A MA55609A MA 55609 A MA55609 A MA 55609A MA 055609 A MA055609 A MA 055609A MA 55609 A MA55609 A MA 55609A MA 55609 A MA55609 A MA 55609A
Authority
MA
Morocco
Prior art keywords
codv
tri
treatment
specific
binding proteins
Prior art date
Application number
MA055609A
Other languages
French (fr)
Inventor
Mangaiarkarasi Asokan
Christian Beil
Jochen Beninga
Joerg Birkenfeld
Mark Connors
Richard A Koup
Young Do Kwon
Peter D Kwong
Qingbo Liu
Paolo Lusso
John R Mascola
Gary J Nabel
Amarendra Pegu
Ercole Rao
Ronnie Wei
Ling Xu
Zhi-Yong Yang
Original Assignee
Sanofi Sa
The United States Of America Represented By The Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, The United States Of America Represented By The Sec Dep Of Health And Human Services filed Critical Sanofi Sa
Publication of MA55609A publication Critical patent/MA55609A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA055609A 2019-04-09 2020-04-08 TRI-SPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING A BI-VARIABLE CROSS-DOMAIN FORMAT (CODV) FOR THE TREATMENT OF HIV INFECTION MA55609A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08

Publications (1)

Publication Number Publication Date
MA55609A true MA55609A (en) 2022-02-16

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055609A MA55609A (en) 2019-04-09 2020-04-08 TRI-SPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING A BI-VARIABLE CROSS-DOMAIN FORMAT (CODV) FOR THE TREATMENT OF HIV INFECTION

Country Status (13)

Country Link
EP (1) EP3953384A1 (en)
JP (1) JP2022526826A (en)
KR (1) KR20210149796A (en)
CN (1) CN114096561A (en)
AU (1) AU2020273156A1 (en)
CA (1) CA3136147A1 (en)
CO (1) CO2021014988A2 (en)
IL (1) IL286932A (en)
MA (1) MA55609A (en)
MX (1) MX2021012384A (en)
SG (1) SG11202111011SA (en)
TW (1) TW202104274A (en)
WO (1) WO2020210386A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
BR112014010823B1 (en) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services antibodies that bind to gp41 and neutralize human immunodeficiency virus type 1 (hiv-1), its uses, nucleic acid molecule, expression vector, composition, kit, as well as methods for detecting hiv-1 infection and potential immunogen test
CN108676091B (en) 2011-12-08 2022-04-01 美国政府(由卫生和人类服务部的部长所代表) Neutralizing antibodies to HIV-1 and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
PE20181167A1 (en) 2015-10-25 2018-07-19 Sanofi Sa TRIESPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR THE PREVENTION OR TREATMENT OF HIV INFECTION
SG11201808911SA (en) 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins

Also Published As

Publication number Publication date
TW202104274A (en) 2021-02-01
AU2020273156A1 (en) 2021-12-02
KR20210149796A (en) 2021-12-09
CO2021014988A2 (en) 2022-01-17
MX2021012384A (en) 2022-02-21
EP3953384A1 (en) 2022-02-16
WO2020210386A1 (en) 2020-10-15
JP2022526826A (en) 2022-05-26
CA3136147A1 (en) 2020-10-15
IL286932A (en) 2021-10-31
CN114096561A (en) 2022-02-25
SG11202111011SA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
FR22C1063I1 (en) THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF HIV VIRUS INFECTION
MA43335B1 (en) Transthyretin (ttr) arni compositions and methods for use thereof for the treatment or prevention of diseases associated with ttr
MY192278A (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
MA48772B1 (en) Kras g12c inhibitors and methods of use thereof
MA52780A (en) KRAS G12C INHIBITORS FOR CANCER TREATMENT
MA52564A (en) KRAS G12C INHIBITORS FOR CANCER TREATMENT
MA53937A (en) COMPOSITIONS COMPRISING BACTERIAL STRAINS
MA42278B1 (en) Compositions comprising a bacterial strains of blautia hydrogenotrophica for use in the treatment of bacterial infections of the gastrointestinal tract
ES2051641B1 (en) PROCEDURES FOR THE PREPARATION OF THIOUREA-DERIVED COMPOUNDS.
PH12020552127A1 (en) Hepatitis b capsid assembly modulators
MA55301A (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
MA52963A (en) TYROSINE PHOSPHATASE PROTEIN INHIBITORS AND PROCEDURES FOR USE
NO20063958L (en) HIV integrase inhibitors
MA51032A (en) USE OF FCRN ANTAGONISTS FOR THE TREATMENT OF GENERALIZED SEVERE MYASTHENIA
MA38208B1 (en) Substituted reverse pyrimidine bmi-1 inhibitors
MA38495A1 (en) Compositions and methods for the diagnosis and treatment of liver cancers
MA49397A (en) POXVIRUS VECTORS CODING FOR HIV ANTIGENS, AND METHODS FOR USING THEM
MA52661A (en) USE OF FUBP1 INHIBITORS IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION
MA53983A (en) 5-MEMBER HETEROARYL CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF HBV
DK1765337T3 (en) Combination of tenofovir, ritonavir and TMC114
MA49131A (en) USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF DISEASE
MA55609A (en) TRI-SPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING A BI-VARIABLE CROSS-DOMAIN FORMAT (CODV) FOR THE TREATMENT OF HIV INFECTION
EA201990988A1 (en) ANTIBODIES AGAINST CHIKV AND WAYS OF THEIR APPLICATION
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
FR3084255B1 (en) STREPTOCOCCUS THERMOPHILUS CNRZ160 STRAIN FOR THE TREATMENT AND PREVENTION OF BOWEL INFLAMMATION AND RELATED DISORDERS IN AN INDIVIDUAL